Identification of Immune Cell Infiltration Landscape and Their Prognostic Significance in Uveal Melanoma

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Sep 13

PMID 34513843

Citations 14

Authors

Han Zhao

Yun Chen

Peijun Shen

Lan Gong

Affiliations

Soon will be listed here.

Abstract

Uveal melanoma (UVM) is the most common primary intraocular cancer in adults. Increasing evidence has demonstrated that immune cell infiltration (ICI) is crucial in predicting patient outcomes and therapeutic efficacy. Thus, describing the immune cell infiltrative landscape of UVM tumors may yield a novel prognostic marker and provide direction for immunotherapeutic selection. In this study, the gene expression data and clinical information of UVM patients were obtained from the cancer genome atlas (TCGA) and gene expression omnibus (GEO) databases. The ICI landscape of UVM was analyzed using the CIBERSORT and ESTIMATE algorithms. Two ICI phenotypes were defined, and the ICI scores were calculated by using principal component analysis algorithms. We found that a subtype with high ICI scores had poorer prognosis and increased expression levels of immune checkpoint-related genes. This study demonstrates that ICI scores are an independent prognostic biomarker and highlights their value in predicting immunotherapeutic outcomes.

Citing Articles

Application of Nanoparticles in the Diagnosis and Treatment of Colorectal Cancer.

Song Q, Zheng Y, Zhong G, Wang S, He C, Li M Anticancer Agents Med Chem. 2024; 24(18):1305-1326.

PMID: 39129164 PMC: 11497148. DOI: 10.2174/0118715206323900240807110122.

Identification and validation of a costimulatory molecule-related signature to predict the prognosis for uveal melanoma patients.

Zhao M, Yu Y, Song Z Sci Rep. 2024; 14(1):9146.

PMID: 38644411 PMC: 11033288. DOI: 10.1038/s41598-024-59827-5.

expression-based prognostic model for uveal melanoma.

Luo Y, Ni R, Jin X, Feng P, Dai C, Jiang L Heliyon. 2023; 9(11):e21333.

PMID: 38027647 PMC: 10651470. DOI: 10.1016/j.heliyon.2023.e21333.

Construction and validation of a novel angiogenesis pattern to predict prognosis and immunotherapy efficacy in colorectal cancer.

Li Z, Liu Y, Guo P, Wei Y Aging (Albany NY). 2023; 15(21):12413-12450.

PMID: 37938164 PMC: 10683615. DOI: 10.18632/aging.205189.

Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma.

Zhao S, Wang Q, Liu Y, Zhang P, Ji W, Xie J BMC Med Genomics. 2023; 16(1):248.

PMID: 37853449 PMC: 10583324. DOI: 10.1186/s12920-023-01688-4.

References

Huang J, Urtatiz O, Van Raamsdonk C . Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice. Cancer Res. 2015; 75(16):3384-97. DOI: 10.1158/0008-5472.CAN-14-3229. View

Thomas S, Putter C, Weber S, Bornfeld N, Lohmann D, Zeschnigk M . Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. Br J Cancer. 2012; 106(6):1171-6. PMC: 3304422. DOI: 10.1038/bjc.2012.54. View

Ishikawa E, Miyazaki T, Takano S, Akutsu H . Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy. Brain Tumor Pathol. 2021; 38(3):149-155. DOI: 10.1007/s10014-021-00402-5. View

Boutros C, Tarhini A, Routier E, Lambotte O, Leroy Ladurie F, Carbonnel F . Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016; 13(8):473-86. DOI: 10.1038/nrclinonc.2016.58. View

Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

Yang X, Li Y, Liu Y, Xu X, Wang Y, Yan Y . Novel circular RNA expression profile of uveal melanoma revealed by microarray. Chin J Cancer Res. 2019; 30(6):656-668. PMC: 6328506. DOI: 10.21147/j.issn.1000-9604.2018.06.10. View

Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A . Current Perspectives in Cancer Immunotherapy. Cancers (Basel). 2019; 11(10). PMC: 6826426. DOI: 10.3390/cancers11101472. View

Egger M, Bhutiani N, Farmer R, Stromberg A, Martin 2nd R, Quillo A . Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes. Surgery. 2016; 159(5):1412-21. DOI: 10.1016/j.surg.2015.12.002. View

Singh A, Turell M, Topham A . Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9):1881-5. DOI: 10.1016/j.ophtha.2011.01.040. View

10.

Garcia-Mulero S, Alonso M, Del Carpio L, Sanz-Pamplona R, Piulats J . Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. Int J Mol Sci. 2021; 22(5). PMC: 7961481. DOI: 10.3390/ijms22052669. View

11.

Sceneay J, Goreczny G, Wilson K, Morrow S, DeCristo M, Ubellacker J . Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discov. 2019; 9(9):1208-1227. PMC: 11167954. DOI: 10.1158/2159-8290.CD-18-1454. View

12.

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E . Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15. DOI: 10.1016/j.ophtha.2007.01.032. View

13.

Wang Y, Xu Y, Dai X, Lin X, Shan Y, Ye J . The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma. Exp Eye Res. 2020; 196:108069. DOI: 10.1016/j.exer.2020.108069. View

14.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

15.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

16.

Algazi A, Tsai K, Shoushtari A, Munhoz R, Eroglu Z, Piulats J . Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016; 122(21):3344-3353. PMC: 5767160. DOI: 10.1002/cncr.30258. View

17.

Kastelan S, Gverovic Antunica A, Beketic Oreskovic L, Pelcic G, Kasun E, Hat K . Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives. Curr Med Chem. 2019; 27(8):1350-1366. DOI: 10.2174/0929867326666190704141444. View

18.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

19.

Bande M, Fernandez-Diaz D, Fernandez-Marta B, Rodriguez-Vidal C, Lago-Baameiro N, Silva-Rodriguez P . The Role of Non-Coding RNAs in Uveal Melanoma. Cancers (Basel). 2020; 12(10). PMC: 7600503. DOI: 10.3390/cancers12102944. View

20.

Javed A, Milhem M . Role of Natural Killer Cells in Uveal Melanoma. Cancers (Basel). 2020; 12(12). PMC: 7764114. DOI: 10.3390/cancers12123694. View